Navigation Links
FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia
Date:8/29/2007

FRAZER, Pa., Aug. 29 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) announced today that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development granted orphan drug designation for the company's investigational therapy, TREANDA(R) (bendamustine HCl), for the treatment of chronic lymphocytic leukemia (CLL). According to the National Cancer Institute, CLL is a slowly progressing blood and bone marrow disease with an estimated 15,000 new cases diagnosed every year in the United States.

Orphan drug status is granted by the FDA to promote the development of products that demonstrate promise for the treatment of rare diseases affecting less than 200,000 Americans annually. The orphan drug designation would entitle Cephalon to a seven-year period of marketing exclusivity in the United States for TREANDA, if approved by FDA for the treatment of CLL.

In the third quarter of 2007, Cephalon plans to submit a new drug application to the FDA for TREANDA for the treatment of patients with CLL. The company also is studying TREANDA for the treatment of patients with indolent (or slowly-progressing) non-Hodgkin's lymphoma (iNHL), who are refractory to the monoclonal antibody rituximab.

Cephalon is committed to advancing medications for orphan diseases. The company's first product, PROVIGIL(R) (modafinil) Tablets [C-IV], was launched with an orphan drug designation for narcolepsy in 1999. Other Cephalon therapies with orphan drug designation include TRISENOX(R) (arsenic trioxide) injection and CEP-701 (lestaurtinib), which is in development.

About TREANDA

TREANDA is the first rationally designed purine analog / alkylator hybrid, combining the moieties of an antimetabolite and an alkylator. Preclinical data show that TREANDA induces rapid, sustained single- and double-strand DNA damage, which results in apoptosis, or programmed cell death in the tumor. TREANDA also induces mitotic checkpoint inhibition, which resu
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. State to offer $850K in high-tech training grants
2. Grants worth $800,000 help BellBrook Labs develop products
3. Venture-backed firms could become eligible for federal SBIR grants
4. Mithridion wins grants for Alzheimers research
5. NASDAQ grants Merge more time for compliance
6. Morgridge seed grants attract over 220 proposals
7. Medical College researchers win federal grants
8. NSF grants bolster integrative graduate study at UW-Madison
9. Three state businesses receive technology grants
10. SBC Foundation awards technology grants in Wisconsin
11. Visonex plans to expand with state grants, loan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... -- The crowdfunding campaign for PosturePulse , a ... popular crowdfunding platform Kickstarter. Backers have already pledged over ... The $75,000 funding goal for the campaign was set ... Photo - http://photos.prnewswire.com/prnh/20140825/139254 ... back that silently vibrates if the wearer slouches for ...
(Date:8/26/2014)... Sauk Rapids, MN (PRWEB) August 26, 2014 ... Products and Assemblies for the Semiconductor, Medical Device, ... is a finalist for the Minnesota Business magazine’s fourth ... This follows the announcement in February that Talon ... (MSJP) Program to develop a robust new training program ...
(Date:8/25/2014)... Spirax Sarco , the leader ... to announce their latest training event: Basic Steam ... being held on December 15 - 19, 2014 at ... where participants will learn virtually all facets of steam ... is exclusively designed for Steam Plant Operations, Steam Plant ...
(Date:8/25/2014)... MONTREAL , Aug. 25, 2014 /CNW Telbec/ - NEOMED, ... bridge between academic research and the pharmaceutical industry, will ... Canada to help academic researchers ... was attained thanks to the success of NEOMED,s application ... "Very early in the creation process of NEOMED, about ...
Breaking Biology Technology:PosturePulse, A Biofeedback Posture-Improving Belt, Improves Posture While Sitting or Standing 2Talon Innovations Selected as Finalist for Minnesota Business Magazine Award 2Talon Innovations Selected as Finalist for Minnesota Business Magazine Award 3Spirax Sarco's Basic Steam Boiler Operator Training Course Is Coming in December to South Carolina 2NEOMED Receives $12 Million from Federal Government 2NEOMED Receives $12 Million from Federal Government 3
... MARINO, Calif., July 8 Epeius Biotechnologies,Corporation today ... by the U.S. Food and Drug Administration (FDA) ... including the rarity,seriousness, and current lack of effective ... and medicinal merit of Rexin-G, the,granting of Orphan ...
... MedPredict Market Research, a,global provider of pharmaceutical ... new report providing critical strategic insight,for pharma ... the market for Rheumatoid,Arthritis (RA) therapies., ... & Analysis: Rheumatoid,Arthritis Q2 2008, MedPredict,s global ...
... tests and evaluations result in 12-years of safe use. , ... St. ... and podcast released today, dietitian Mary Lee Chin describes the ... genetically modified foods. In the video, Chin discusses how consumers on a ...
Cached Biology Technology:Epeius Biotechnologies' Tumor-Targeted Rexin-G Receives FDA Orphan Drug Designation for the Treatment of Osteosarcoma 2New MedPredict Report Highlights Trend Toward Early Diagnosis and Treatment of Rheumatoid Arthritis, Impact on Pharmaceutical Development 2Dietitian Mary Lee Chin Comments on Proven Value and Safety of Food Biotechnology in New Online Video 2Dietitian Mary Lee Chin Comments on Proven Value and Safety of Food Biotechnology in New Online Video 3Dietitian Mary Lee Chin Comments on Proven Value and Safety of Food Biotechnology in New Online Video 4
(Date:8/26/2014)... mathematical sciences at New Jersey Institute of Technology (NJIT), ... clock that sets the pace for daily life. , ... other mammals with fundamental rhythms of life that include ... and with seasonal change. The brain,s circadian clock controls ... which, when disrupted by experiences such as jet lag ...
(Date:8/26/2014)... combining plasmonics and optical microresonators, researchers at the ... new optical amplifier (or laser) design, paving the ... made optical systems at the microscopic scale that ... J. Gary Eden, a professor of electrical and ... amplifiers are well-suited for routing optical power on ...
(Date:8/26/2014)... the University of Liverpool has recommended investing in dog owner ... and problems such as obesity in both people and their ... 1990, the researchers found that access to dog-friendly walking environments ... people to get out and take more exercise with their ... don,t take their dogs for a walk. In the UK, ...
Breaking Biology News(10 mins):Researching fundamental rhythms of life 2Researching fundamental rhythms of life 3Symphony of nanoplasmonic and optical resonators produces laser-like light emission 2Education and dog-friendly neighbourhoods could tackle obesity 2
... Research Center Oakland is the first children,s hospital in ... the way blood is analyzed at pediatric hospitals. This ... in some debit or credit cards at the supermarket ... The procedure starts with a respiratory therapist who ...
... A recent study conducted in the Midwestern United States ... cultivated and uncultivated soils, vastly advancing the knowledge of ... soil attribute that is related to the physical-chemical state ... processes that determine soil quality. During the wet season ...
... years after the AIDS epidemic spawned a worldwide search ... (HIV), progress in the field seems to have effectively ... a team of researchers from the California Institute of ... fact that our body,s natural HIV antibodies simply don,t ...
Cached Biology News:Children's Hospital Oakland is first pediatric hospital to use 'laboratory-on-a-card' technology 2Impact of floods on soils 2Caltech scientists show why anti-HIV antibodies are ineffective at blocking infection 2Caltech scientists show why anti-HIV antibodies are ineffective at blocking infection 3